BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26648328)

  • 21. [Suppression of NR0B2 gene in Clear Cell Renal Cell Carcinoma Is Associated with Hypermethylation of Its Promoter].
    Kudryavtseva AV; Nyushko KM; Zaretsky AR; Shagin DA; Sadritdinova AF; Fedorova MS; Savvateeva MV; Guvatova ZG; Pudova EA; Alekseev BY; Dmitriev AA; Snezhkina AV
    Mol Biol (Mosk); 2018; 52(3):482-488. PubMed ID: 29989580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.
    Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Maslowski Z; Kmiec Z
    Anticancer Res; 2016 Feb; 36(2):617-24. PubMed ID: 26851016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The long non-coding RNA
    Calanca N; Paschoal AP; Munhoz ÉP; Galindo LT; Barbosa BM; Caldeira JRF; Oliveira RA; Cavalli LR; Rogatto SR; Rainho CA
    Epigenetics; 2019 Aug; 14(8):741-750. PubMed ID: 31062660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
    Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
    Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
    BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
    Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
    Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
    Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
    JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
    Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
    Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma.
    Zhou J; Deng Z; Chen Y; Gao Y; Wu D; Zhu G; Li L; Song W; Wang X; Wu K; He D
    Urol Oncol; 2015 Mar; 33(3):113.e9-17. PubMed ID: 25192834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
    Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
    Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma.
    Yamada D; Kikuchi S; Williams YN; Sakurai-Yageta M; Masuda M; Maruyama T; Tomita K; Gutmann DH; Kakizoe T; Kitamura T; Kanai Y; Murakami Y
    Int J Cancer; 2006 Feb; 118(4):916-23. PubMed ID: 16152585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
    Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
    BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection.
    Liu ZJ; Huang Y; Wei L; He JY; Liu QY; Yu XQ; Li ZL; Zhang J; Li B; Sun CJ; Liang WB; Sun AM; Qin Y
    Neoplasma; 2017; 64(5):795-802. PubMed ID: 28592132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression of RASSF1A and RASSF1C transcripts in human primary ovarian cancers].
    Ma L; Zhang JH; Liu FR; Zhang X
    Zhonghua Bing Li Xue Za Zhi; 2005 Mar; 34(3):150-3. PubMed ID: 15938825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene.
    Li J; Wang F; Protopopov A; Malyukova A; Kashuba V; Minna JD; Lerman MI; Klein G; Zabarovsky E
    Oncogene; 2004 Aug; 23(35):5941-9. PubMed ID: 15208682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.